Exchange: NASDAQ·Updated 07:34 PM EDT
GANX logo

GANXGain Therapeutics Inc

$1.84
$0.21
(12.88%)
Today
Closed $1.84
$0.0003
(0.02%)
After Hours
Reported EarningsMay 11
Mkt Cap$69.53M
Vol682,764.00
News
all
press releases
Why Is GANX Stock Rallying 22% After Hours?
The U.S. Food and Drug Administration (FDA) cleared Gain Therapeutics to begin a mid-stage clinical trial of its experimental drug GT-02287 in people with Parkinson’s disease.
Stocktwits
More News
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market session. The market value of their outstanding shares is at $74.6 million. BNB Plus (NASDAQ:BNBX) stock rose 9.78% toread more...
Benzinga
Gain Therapeutics (NASDAQ:GANX) Stock Price Up 1.1% - Here's Why
Gain Therapeutics (NASDAQ:GANX) Stock Price Up 1.1% - Here's Why...
MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, MarketBeat...
MarketBeat
HC Wainwright Has Positive Estimate for GANX Q1 Earnings
Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for Gain Therapeutics in a research note issued on Monday, March 30th. HC Wainwright...
MarketBeat
Gain Therapeutics (NASDAQ:GANX) Issues Earnings Results
Gain Therapeutics (NASDAQ:GANX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03...
MarketBeat
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference
Gain Therapeutics (NASDAQ:GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead focus on Parkinson's disease, company CEO Gene Mack said during a fireside...
MarketBeat
Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday
Gain Therapeutics (NASDAQ:GANX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...
MarketBeat
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% - What's Next?
Gain Therapeutics (NASDAQ:GANX) Stock Price Up 3.7% - Should You Buy...
MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.